^
Association details:
| Biomarker: | HER-2 amplification + RAS wild-type + BRAF wild-type |
|---|---|
| Cancer: | Rectal Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Perjeta (pertuzumab) (HER2 dimerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Rectal cancer: Systemic therapy for advanced or metastatic disease…Trastuzumab + Pertuzumab...(HER2-amplified and RAS and BRAF WT)
